Drug Innovation
Commentary
Don’t Slash Medicare In Last – Minute Budget Agreement
The weather isn’t the only thing heating up in Washington. White House officials are feverishly negotiating with congressional leaders to raise the debt ceiling and reach a two-year budget deal that averts more than $126 billion in automatic spending cuts. Democrats want the deal to dramatically raise domestic spending levels. Republicans ...
Drug Innovation
Wayne Winegarden Biosimilar Study Featured in Fierce Healthcare
Report: Growing biosimilar market could save billions in health spending By Paige Minemyer Growing the biosimilar market could lead to significant healthcare cost savings, according to a new report, with the opportunity for billions in cost reductions. An analysis (PDF) from the Pacific Research Institute, a free market think tank, shows today ...
Drug Innovation
PRI’s biosimilars study featured in Politico’s Prescription Pulse newsletter
The Pacific Research Institute’s Center for Medical Economics and Innovation study on biosimilars was published in Politico’s Prescription Pulse newsletter.
Commentary
How socialist price controls will harm American patients
The Trump administration is planning to propose one of the biggest changes to Medicare in decades. The draft rule aims to reduce government spending by linking Medicare drug reimbursement rates to the rates in more than a dozen other Western countries that use price controls to hold down pharmaceutical spending. If implemented, ...
Business & Economics
Protecting The Medicines Of Tomorrow
Government solutions often come with a price. For the America Invents Act (AIA), this price was an unintended impediment to medical innovation. Proposed legislation known as the Hatch-Waxman Integrity Act can reduce these costs, if Congress takes advantage of the opportunity. The problem of patent trolls plaguing Silicon Valley was ...
Business & Economics
Embracing Competition To Empower Biosimilars
In 2017, there were 46 new novel drug innovations, including new treatments for cancers, Parkinson’s disease, and serious skin infections. These innovations are essential for improving the quality of health care in the U.S. However, innovation is not sufficient. It is equally imperative to promote drug affordability through greater competition. Promoting ...
Business & Economics
Strike The Right Regulatory Balance To Promote Generic Medicines And Future Innovation
Striking the right regulatory balance for pharmaceuticals is no easy task. On the one hand, policy should promote drug affordability by encouraging robust competition. On the other hand, policy should encourage future innovations by granting these drugs temporary market exclusivity. While these goals appear contradictory, the federal government’s drug approval ...
Business & Economics
Price Controls Will Reduce Innovation and Health Outcomes
Abraham Kaplan famously noted that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” Put differently, solving problems requires the right tool, not the convenient tool. Congress should remember this wisdom in its upcoming deliberations regarding the cost of prescription drugs. The ...
Business & Economics
Reforming the 340B Program Will Lower the Price of Prescription Drugs
The U.S. health care system needs systemic reforms that comprehensively address the problems of declining quality and rising costs. Alas, beneficial systemic reforms will not be implemented any time soon. There are still opportunities for Congress to implement tailored reforms that can help address these problems in the near term. ...
Blog
A Scientific Basis for the EPA on the Clean Power Plan
EPA Administrator Scott Pruitt will make official on Tuesday what we knew all along – the Administration is officially withdrawing the controversial Clean Power Plan rule on power plant emissions. California Attorney General Xavier Becerra has railed against the repeal of the Clean Power Plan (CPP) claiming that the EPA’s ...
Don’t Slash Medicare In Last – Minute Budget Agreement
The weather isn’t the only thing heating up in Washington. White House officials are feverishly negotiating with congressional leaders to raise the debt ceiling and reach a two-year budget deal that averts more than $126 billion in automatic spending cuts. Democrats want the deal to dramatically raise domestic spending levels. Republicans ...
Wayne Winegarden Biosimilar Study Featured in Fierce Healthcare
Report: Growing biosimilar market could save billions in health spending By Paige Minemyer Growing the biosimilar market could lead to significant healthcare cost savings, according to a new report, with the opportunity for billions in cost reductions. An analysis (PDF) from the Pacific Research Institute, a free market think tank, shows today ...
PRI’s biosimilars study featured in Politico’s Prescription Pulse newsletter
The Pacific Research Institute’s Center for Medical Economics and Innovation study on biosimilars was published in Politico’s Prescription Pulse newsletter.
How socialist price controls will harm American patients
The Trump administration is planning to propose one of the biggest changes to Medicare in decades. The draft rule aims to reduce government spending by linking Medicare drug reimbursement rates to the rates in more than a dozen other Western countries that use price controls to hold down pharmaceutical spending. If implemented, ...
Protecting The Medicines Of Tomorrow
Government solutions often come with a price. For the America Invents Act (AIA), this price was an unintended impediment to medical innovation. Proposed legislation known as the Hatch-Waxman Integrity Act can reduce these costs, if Congress takes advantage of the opportunity. The problem of patent trolls plaguing Silicon Valley was ...
Embracing Competition To Empower Biosimilars
In 2017, there were 46 new novel drug innovations, including new treatments for cancers, Parkinson’s disease, and serious skin infections. These innovations are essential for improving the quality of health care in the U.S. However, innovation is not sufficient. It is equally imperative to promote drug affordability through greater competition. Promoting ...
Strike The Right Regulatory Balance To Promote Generic Medicines And Future Innovation
Striking the right regulatory balance for pharmaceuticals is no easy task. On the one hand, policy should promote drug affordability by encouraging robust competition. On the other hand, policy should encourage future innovations by granting these drugs temporary market exclusivity. While these goals appear contradictory, the federal government’s drug approval ...
Price Controls Will Reduce Innovation and Health Outcomes
Abraham Kaplan famously noted that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” Put differently, solving problems requires the right tool, not the convenient tool. Congress should remember this wisdom in its upcoming deliberations regarding the cost of prescription drugs. The ...
Reforming the 340B Program Will Lower the Price of Prescription Drugs
The U.S. health care system needs systemic reforms that comprehensively address the problems of declining quality and rising costs. Alas, beneficial systemic reforms will not be implemented any time soon. There are still opportunities for Congress to implement tailored reforms that can help address these problems in the near term. ...
A Scientific Basis for the EPA on the Clean Power Plan
EPA Administrator Scott Pruitt will make official on Tuesday what we knew all along – the Administration is officially withdrawing the controversial Clean Power Plan rule on power plant emissions. California Attorney General Xavier Becerra has railed against the repeal of the Clean Power Plan (CPP) claiming that the EPA’s ...
